Commercialization

Vivici Selects Ginkgo Bioworks to Extend Their Range of Novel Dairy Proteins

Retrieved on: 
Monday, November 27, 2023
NYSE, DNA, Senior, Protein, Fermentation, DSM, Ginkgo Bioworks, Partnership, Commercialization, Food preservation, Vaccine, Ginkgo

Vivici has formed a partnership with Ginkgo to advance production of a sustainable and nutritious dairy protein, made via precision fermentation.

Key Points: 
  • Vivici has formed a partnership with Ginkgo to advance production of a sustainable and nutritious dairy protein, made via precision fermentation.
  • Ginkgo will use its Protein Production Services and generative AI platform to deliver best-in-class candidate strains to Vivici.
  • Vivici will use the strains from this collaboration to extend their existing range of proteins, supporting innovative specialised nutrition companies, to bring planet-friendly nutrition to consumers.
  • Recognizing the need for alternatives to traditional animal agriculture, Vivici employs precision fermentation techniques to produce animal-free dairy proteins with microorganisms.

Vivici Selects Ginkgo Bioworks to Extend Their Range of Novel Dairy Proteins

Retrieved on: 
Monday, November 27, 2023
NYSE, DNA, Senior, Protein, Fermentation, DSM, Ginkgo Bioworks, Partnership, Commercialization, Food preservation, Vaccine, Ginkgo

Vivici has formed a partnership with Ginkgo to advance production of a sustainable and nutritious dairy protein, made via precision fermentation.

Key Points: 
  • Vivici has formed a partnership with Ginkgo to advance production of a sustainable and nutritious dairy protein, made via precision fermentation.
  • Ginkgo will use its Protein Production Services and generative AI platform to deliver best-in-class candidate strains to Vivici.
  • Vivici will use the strains from this collaboration to extend their existing range of proteins, supporting innovative specialised nutrition companies, to bring planet-friendly nutrition to consumers.
  • Recognizing the need for alternatives to traditional animal agriculture, Vivici employs precision fermentation techniques to produce animal-free dairy proteins with microorganisms.

Infleqtion Joins U.S. Department of Energy (DOE)'s Quantum & Space Collaboration

Retrieved on: 
Monday, November 13, 2023
Unify, Generate, Quantum, Navigation, PNT, ISS, Research, Department of Defence, Air Force Research Laboratory, Primary energy, Information science, Collection, Integration, History, NASA, ISR, Collaboration, OTT, Party, Intelligence, Nuclear energy, Physics, Accenture, Partnership, DOE, DOD, Technological transitions, Commercialization, Bose–Einstein, Office of Electricity, Renewable energy, Electronics, Microscope, Risk management, Orbit, Defense, Atomtronics, Electricity

AUSTIN, Texas, Nov. 13, 2023 /PRNewswire/ -- The U.S. Department of Energy (DOE), alongside a cohort of strategic partners, today announced the first round of participants dedicated to the Quantum & Space Collaboration. This collaborative effort aims to harness cutting-edge quantum technologies for pivotal advancements in national security, energy, and economic prosperity, while also supporting sustainability goals.

Key Points: 
  • AUSTIN, Texas, Nov. 13, 2023 /PRNewswire/ -- The U.S. Department of Energy (DOE), alongside a cohort of strategic partners, today announced the first round of participants dedicated to the Quantum & Space Collaboration.
  • The Quantum & Space Collaboration has garnered an array of participants, including the DOE, Department of Defense (DOD), Infleqtion , Nebula Space Enterprises, and Accenture Federal Services.
  • Together, we will harness the power of quantum sensing, quantum communications, and quantum computing to advance national security, energy, and economic interests," said Scott Faris, CEO of Infleqtion .
  • These range from quantum information science, quantum security and AI/machine learning to fortifying the pursuit of quantum applications and space demonstrations.

Micro-LED Displays: IDTechEx Explores the Future of Visual Excellence

Retrieved on: 
Monday, November 13, 2023
Light-emitting diode, MicroLED, Panasonic, Investment, Tablet, Virtual reality, LG, LED, LG Display, Rest, OLED, Micrometer, Television, R, LCD, VR, Knowledge, JDI, Innovation system, Commercialization, Players, Samsung, Printed circuit board, Video game, Retail, Consumer electronics

With global dynamics rapidly evolving, it is essential to understand how this groundbreaking technology is shaping the future of the display industry.

Key Points: 
  • With global dynamics rapidly evolving, it is essential to understand how this groundbreaking technology is shaping the future of the display industry.
  • IDTechEx's report " Micro-LED Displays 2024-2034: Technology, Commercialization, Opportunity, Market and Players " explores various angles of Micro-LED displays.
  • Discover the future of visual excellence with Micro-LED displays.
  • Dr Xiaoxi He, Research Director at IDTechEx and author of this article, will be presenting a free-to-attend webinar on the topic on Thursday 30 November 2023 - MicroLED Displays: Unveiling the Future of Visual Excellence .

Micro-LED Displays: IDTechEx Explores the Future of Visual Excellence

Retrieved on: 
Monday, November 13, 2023
Light-emitting diode, MicroLED, Panasonic, Investment, Tablet, Virtual reality, LG, LED, LG Display, Rest, OLED, Micrometer, Television, R, LCD, VR, Knowledge, JDI, Innovation system, Commercialization, Players, Samsung, Printed circuit board, Video game, Retail, Consumer electronics

With global dynamics rapidly evolving, it is essential to understand how this groundbreaking technology is shaping the future of the display industry.

Key Points: 
  • With global dynamics rapidly evolving, it is essential to understand how this groundbreaking technology is shaping the future of the display industry.
  • IDTechEx's report " Micro-LED Displays 2024-2034: Technology, Commercialization, Opportunity, Market and Players " explores various angles of Micro-LED displays.
  • Discover the future of visual excellence with Micro-LED displays.
  • Dr Xiaoxi He, Research Director at IDTechEx and author of this article, will be presenting a free-to-attend webinar on the topic on Thursday 30 November 2023 - MicroLED Displays: Unveiling the Future of Visual Excellence .

Cerba HealthCare Changes Its Governance and Appoints Emmanuel Ligner Group Chief Executive Officer

Retrieved on: 
Thursday, November 9, 2023
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Otsuka Pharmaceutical, Abbott, Iveco, Exor, History, Leo Pharma, Pathology, Zodiac Aerospace, HTL, CGG, Development, Procter & Gamble, Commercialization, GE, Supervisory board, Procter, Senior advisor, ICON PLC, Stellantis, Pharmaceutical industry, Management, Allergan, Thales of Miletus

Cerba HealthCare, a leading player in medical diagnostics, announces the appointment of Emmanuel Ligner as Chief Executive Officer of the Group.

Key Points: 
  • Cerba HealthCare, a leading player in medical diagnostics, announces the appointment of Emmanuel Ligner as Chief Executive Officer of the Group.
  • Cerba HealthCare aims to remain at the forefront of medical innovation to help develop new treatments and improve patient health.
  • Emmanuel Ligner, Group Chief Executive Officer, said: « Cerba HealthCare is a leading company in the field of medical diagnostics as evidenced by the Group’s growth and the importance it has placed on innovation since its very inception.
  • »
    Jérôme Thill, Senior Advisor and former Chief Executive Officer of the Group, adds: « As I step down as Chief Executive Officer, I would like to thank all of Cerba HealthCare’s teams and partners.

MoonFox Data: Image-Text Content, Hot Items, and Seeding Drive the Rapid Growth of RED Community

Retrieved on: 
Wednesday, November 8, 2023
PUGC, UI, Female, Publishing, Data collection, Unique, Acceleration, Judgement, Data source, Commercialization, WeChat, Growth, City, Transport, IAPP, Marketing, Travel, Algorithm, RED, Online shopping, Mobile phone

The attributes of users give brands their tone, and RED's community tone aligns well with the direction of store-exploring.

Key Points: 
  • The attributes of users give brands their tone, and RED's community tone aligns well with the direction of store-exploring.
  • Formal data indicates that in 2022, there were more than tens of millions of notes on RED pertaining to "food-exploring."
  • After completing the search and browsing seeding content, users will no longer need to exit RED and open other platforms to check prices.
  • In summary, the commercialization of RED, which has experienced rapid growth, is an important battle that cannot be avoided.

OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Eli Lilly and Company, IND, NYSE, LXR, DSM-IV codes, Obesity, LLY, MD, Doctor of Philosophy, Agonal respiration, Commercialization, NASH, Cancer, ACMSD, Series, Patient, Pharmaceutical industry, Nursing, Saṃsāra

The financing, which will support the advancement of OrsoBio’s obesity-focused portfolio, was co-led by Longitude Capital and Enavate Sciences.

Key Points: 
  • The financing, which will support the advancement of OrsoBio’s obesity-focused portfolio, was co-led by Longitude Capital and Enavate Sciences.
  • OrsoBio will utilize the Series A funding to advance the development of its innovative portfolio of four programs focused on obesity and associated metabolic disorders.
  • ACMSD inhibitor (aminocarboxymuconate semialdehyde decarboxylase inhibitor): Selection of a development candidate for potential treatment of metabolic and inflammatory liver and kidney disorders and advancement of IND-enabling activities.
  • “We are grateful for the continued trust in our team and commitment to our mission to improve clinical outcomes in patients with obesity and associated metabolic disorders.

IntegriChain Presents The Tina Patel Shining Light Award to Patrick Townsend of Vertex Pharmaceuticals

Retrieved on: 
Tuesday, November 7, 2023
Gene editing, FDA, Janssen, Alexion, Hematology, Partner (business rank), Courage, CRISPR, Conference, Entrepreneurship, Access, Senior, Townsend, Commercialization, Gamer, Boehringer Ingelheim, Paradox Access Solutions, Partnership, Market access, Cystic fibrosis, Service, Vertex Pharmaceuticals, Patient, Alexion Pharmaceuticals, Memory, Pharmaceutical industry, Fine chemical, Management, Vertex

PHILADELPHIA, Nov. 7, 2023 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, announced the winners of its annual customer awards today at the Access Insights Conference, co-hosted with Blue Fin Group. IntegriChain presented a new award, The Tina Patel Bright Light Award, to Patrick Townsend, Director of Distribution Strategy, at Vertex Pharmaceuticals. IntegriChain also presented its Commercialization Visionary Award to Johnson & Johnson Innovative Medicine, the Lighthouse Award to Alexion Pharmaceuticals, and the Zero to Launch Award to Tarsus Pharmaceuticals.

Key Points: 
  • IntegriChain presented a new award, The Tina Patel Bright Light Award, to Patrick Townsend , Director of Distribution Strategy, at Vertex Pharmaceuticals .
  • IntegriChain also presented its Commercialization Visionary Award to Johnson & Johnson Innovative Medicine , the Lighthouse Award to Alexion Pharmaceuticals , and the Zero to Launch Award to Tarsus Pharmaceuticals .
  • The Tina Patel Bright Light Award is presented in memory of Tina Patel, Vice President, Market Access Marketing, for Boehringer Ingelheim.
  • The Tinal Patel Shining Light Award: Patrick Townsend, Vertex Pharmaceuticals
    Townsend leads distribution strategy at Vertex.

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

Retrieved on: 
Friday, November 3, 2023
FDA, Research, Regenerative Medicine Advanced Therapy, Food, Spinal muscular atrophy, Biogen, SCD, Life, Public expenditure, TDT, Cas9, Sickle cell disease, Regulation of tobacco by the U.S. Food and Drug Administration, Poster, Society, ASH, Commercialization, HSC, File, Fetal hemoglobin, Collaboration, Lead, Beta thalassemia, Anemia, Multiple sclerosis, Bone marrow, Therapy, Patient, BLA, MS, Pharmaceutical industry, Cryptocurrency, Edith A. Perez, Editas Medicine, EU

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the third quarter 2023 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the third quarter 2023 and provided business updates.
  • Cash, cash equivalents, and marketable securities as of September 30, 2023, were $446.4 million compared to $480.0 million as of June 30, 2023.
  • The increase is primarily related to an upfront payment for the non-exclusive Cas9 license to Vor Bio in the third quarter of 2023.
  • Editas Medicine plans to participate in the following scientific and medical conference:
    Editas Medicine plans to participate in the following investor events: